Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus sintilimab as first-line therapy for unresectable advanced or metastatic biliary tract cancer
ChiCTR2100050590Phase 4Recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib and sintilimab in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: objective response rate. Started Sep 2021; status: recruiting.
02
Drugs
anlotinibsintilimab
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2100050590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050590.